Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

BioRestorative Therapies Inc BRTX

BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.


NDAQ:BRTX - Post by User

User Avatar Image
(10)
•••
  • MikeTesterX
Post by MikeTesteron Jan 24, 2025 5:37pm
29 Views
Post# 36419891

BioRestorative Therapies (BRTX): Pioneering Cell-Based Thera

BioRestorative Therapies (BRTX): Pioneering Cell-Based TheraLooks like BRTX is making some serious moves in the cell therapy space. Those Phase 2 trial results are looking spicy - 70% of patients seeing over 30% improvement in pain and function is no joke. The aesthetics partnership with Cartessa and $13.1M cash position gives them some runway. Might be worth a small speculative position given the potential in regenerative medicine.BeyondSPX continues to deliver high quality in-depth analysis on just about every US stock out there, even microcaps, for free. Solid research platform.Watching this one closely. Could be a breakout candidate if Phase 2 continues to show strong signals.                         https://beyondspx.com/article/biorestorative-therapies-brtx-pioneering-cell-based-therapies-for-chronic-diseases





<< Previous
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities